Oncomed Pharmaceuticals Inc., of Redwood City, Calif., presented data from two phase Ib trials of demcizumab (anti-DLL4, OMP-21M18) in pancreatic cancer and non-small-cell lung cancer (NSCLC), demonstrating that the drug, in combination with standard-of-care chemotherapy, was well tolerated, especially in patients where the company's risk mitigation, monitoring and truncated dosing strategies have been employed.